These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 25833329

  • 1. Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases.
    Siva S, Callahan JW, Kron T, Chesson B, Barnett SA, Macmanus MP, Hicks RJ, Ball DL.
    Acta Oncol; 2015; 54(8):1105-12. PubMed ID: 25833329
    [Abstract] [Full Text] [Related]

  • 2. Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy.
    Siva S, Chesson B, Callahan JW, Hardcastle N, Crawford L, Antippa P, Wright G, MacManus MP, Hicks RJ, Kron T, Ball DL.
    J Thorac Oncol; 2015 Jul; 10(7):1112-5. PubMed ID: 26134229
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
    Siva S, Kirby K, Caine H, Pham D, Kron T, Te Marvelde L, Whalley D, Stevens MJ, Foroudi F, MacManus M, Ball D, Eade T.
    Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
    [Abstract] [Full Text] [Related]

  • 4. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18FDG-PET/CT.
    Mazzola R, Fiorentino A, Di Paola G, Giaj Levra N, Ricchetti F, Fersino S, Tebano U, Pasetto S, Ruggieri R, Salgarello M, Alongi F.
    J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
    Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, Takahashi T, Kajihara M, Teramoto N, Yamashita M, Mochizuki T.
    Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R, Bohn P, Gardin I, Vera P.
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [Abstract] [Full Text] [Related]

  • 9. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
    Farid K, Poullias X, Alifano M, Regnard JF, Servois V, Caillat-Vigneron N, Petras S.
    Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
    [Abstract] [Full Text] [Related]

  • 10. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):e551-5. PubMed ID: 22417800
    [Abstract] [Full Text] [Related]

  • 11. CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy.
    Sawyer B, Pun E, Samuel M, Tay H, Kron T, Bressel M, Ball D, Siva S.
    J Med Imaging Radiat Oncol; 2015 Apr 15; 59(2):207-15. PubMed ID: 25601133
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning.
    Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB.
    Int J Radiat Oncol Biol Phys; 2012 Jan 01; 82(1):e99-105. PubMed ID: 21377285
    [Abstract] [Full Text] [Related]

  • 14. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
    Hardcastle N, Hofman MS, Lee CY, Callahan J, Selbie L, Foroudi F, Shaw M, Chander S, Lim A, Chesson B, Murphy DG, Kron T, Siva S.
    Radiat Oncol; 2019 Sep 05; 14(1):164. PubMed ID: 31488175
    [Abstract] [Full Text] [Related]

  • 15. Defining target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional 18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography.
    Hanna GG, van Sörnsen de Koste JR, Dahele MR, Carson KJ, Haasbeek CJ, Migchielsen R, Hounsell AR, Senan S.
    Clin Oncol (R Coll Radiol); 2012 Aug 05; 24(6):e71-80. PubMed ID: 22445302
    [Abstract] [Full Text] [Related]

  • 16. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM.
    J Nucl Med; 2013 Oct 05; 54(10):1710-6. PubMed ID: 23970365
    [Abstract] [Full Text] [Related]

  • 17. Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumes.
    Callahan J, Kron T, Siva S, Simoens N, Edgar A, Everitt S, Schneider ME, Hicks RJ.
    Radiat Oncol; 2014 Dec 16; 9():291. PubMed ID: 25511904
    [Abstract] [Full Text] [Related]

  • 18. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S.
    Lancet Oncol; 2012 Aug 16; 13(8):802-9. PubMed ID: 22727222
    [Abstract] [Full Text] [Related]

  • 19. PET motion compensation for radiation therapy using a CT-based mid-position motion model: methodology and clinical evaluation.
    Kruis MF, van de Kamer JB, Houweling AC, Sonke JJ, Belderbos JS, van Herk M.
    Int J Radiat Oncol Biol Phys; 2013 Oct 01; 87(2):394-400. PubMed ID: 23910710
    [Abstract] [Full Text] [Related]

  • 20. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
    Yap ML, Sun A, Higgins J, Clarke K, Marshall A, Becker N, Le LW, Vines DC, Bezjak A, Bissonnette JP.
    Clin Oncol (R Coll Radiol); 2016 Dec 01; 28(12):e199-e205. PubMed ID: 27637725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.